Format

Send to

Choose Destination
Trends Microbiol. 1997 Jun;5(6):240-9.

Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance.

Author information

1
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. nicas_thalia_r@lilly.com

Abstract

The incidence of infections caused by resistant Gram-positive pathogens is increasing, while emergence of vancomycin resistance is reducing the number of therapeutic options. New agents are being rapidly evaluated as candidates to replace vancomycin; some of the most promising include semisynthetic glycopeptides, quinupristin-dalfopristin, oxazolidinones and everninomycins. Alternative strategies, including immunization and therapeutic vaccines, may also have a role.

PMID:
9211645
DOI:
10.1016/S0966-842X(97)01051-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center